The Rabbit IL-8 (CXCL8) polyclonal antibody is unlabeled and has been qualified for use in ELISA and Western blot applications. It is the capture antibody in the Kingfisher Biotech Rabbit IL-8 ELISA. The Rabbit IL-8 polyclonal antibody was produced in goats and is antigen-affinity purified. The reactivity by species is: (Bovine IL-8 - None) (Canine IL-8 - None) (Catfish IL-8 - None) (Chicken IL-8 - None) (Dolphin IL-8 - Weak) (Equine IL-8 - None) (Feline IL-8 - None) (Guinea Pig IL-8 - Strong) (Human IL-8 - Strong) (Ovine IL-8 - None) (Rabbit IL-8 - Strong) (Swine IL-8 - Weak) (Turkey IL-8 - None). For research use only.
Rabbit Interleukin-8 (IL-8), also known as CXCL8, is a potent pro-inflammatory chemokine that plays a central role in innate immune responses in rabbits (Oryctolagus cuniculus) by mediating neutrophil chemotaxis, activation, and recruitment to sites of infection or tissue injury. Produced by macrophages, epithelial cells, endothelial cells, and fibroblasts in response to microbial products and inflammatory cytokines, rabbit IL-8 signals primarily through CXCR1 and CXCR2 receptors to promote rapid neutrophil migration and amplification of local inflammatory responses. Elevated IL-8 expression is observed in bacterial infections such as Pasteurella multocida, viral diseases including rabbit hemorrhagic disease virus (RHDV), and in models of pulmonary inflammation, wound healing, and arthritis, where neutrophil-driven inflammation contributes to both pathogen clearance and tissue pathology. As a biomarker, IL-8 is useful for assessing inflammatory status and disease progression in laboratory and veterinary settings. In translational research, rabbits serve as important models for respiratory disease, atherosclerosis, osteoarthritis, ophthalmic inflammation, and vaccine development, and characterization of IL-8 in these systems enhances understanding of neutrophil-mediated tissue injury, chemokine signaling pathways, and therapeutic strategies targeting inflammatory cascades relevant to human disease.